Entrada Therapeutics Financials - Benzinga

Entrada Therapeutics Inc

TRDANASDAQ

Trade with Public

Trade with Public

$7.09

-0.18-2.48%

Last update: Aug 28, 7:06 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Entrada Therapeutics Financials

Entrada Therapeutics (TRDA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Entrada Therapeutics Q2 EPS $(1.01) Beats $(1.09) Estimate, Sales $898.000K Beat $411.429K Estimate

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.09) by 7.34 percent. This is a 2.88 percent increase over losses of $(1.04) per share

Benzinga Newsdesk

PRO
Entrada Therapeutics Q1 EPS $(0.95) Beats $(1.09) Estimate, Sales $875.000K Miss $1.393M Estimate

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.09) by 12.84 percent. This is a 126.19 percent decrease over losses of $(0.42) per share

Benzinga Newsdesk

Earnings Summary: Entrada Therapeutics Q4

Benzinga Insights

PRO
Entrada Therapeutics Q4 EPS $(0.94) Beats $(1.07) Estimate, Sales $1.299M Miss $13.886M Estimate

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.4 percent. This is a 3233.33 percent decrease over earnings of $0.03 per share

Benzinga Newsdesk

PRO
Entrada Therapeutics Q3 EPS $(1.06) Misses $(0.95) Estimate, Sales $1.614M Miss $13.702M Estimate

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.95) by 11.58 percent. This is a 202.86 percent decrease over losses of $(0.35) per

Benzinga Newsdesk

PRO
Entrada Therapeutics Q2 EPS $(1.04) Misses $(0.85) Estimate, Sales $1.950M Miss $9.651M Estimate

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.85) by 22.64 percent. This is a 167.1 percent decrease over earnings of $1.55 per share

Benzinga Newsdesk